Aimovig Comp Plan Is A JOKE

Discussion in 'Amgen' started by anonymous, Jun 11, 2018 at 4:51 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    100% correct look at the leader board Chicago is the winner why work. Of offense to the reps but not matter who was there they would of put in 300 forms in 2 weeks.
     

  2. anonymous

    anonymous Guest


    Diamond has lists of hundreds.
     
  3. anonymous

    anonymous Guest

    Inaccurate, Lilly will take the cake 4q. Some fed up headquarter employees are headed to Lilly and will probably recruit the best reps and managers to join them. These big migraine centers/customers will quickly join hands with the Amgen hq detractors. It's about relationships, not price, efficacy or the hub. Amgen is arrogant now but the franchise will be left in ashes come 4q.
     
  4. anonymous

    anonymous Guest


    Hold on a minute Sparky....You might want to take a look at the facts. Teva is starting to get a few of those key folks and will fill vacancies long before Lilly even gets a sniff at their product launch, if it even happens in Q4.
     
  5. anonymous

    anonymous Guest

    I'm a migraine patient. I wish I never found my way here. But I hope you all get fair comp and big $$ especially if it's effective. I'm about to dig out my eye.
     
  6. anonymous

    anonymous Guest

    I'm a patient and wish I never found this. But I hope you all get your comp.
     
  7. anonymous

    anonymous Guest

    BS. Amgen is fully human. Lilly's not as good. Teva is not as good. Amgen rules. Aimovig is the best.

    Comp plan does stink. Only the territories with migraine centers win. We all know that. Top cities with huge headache centers.
     
  8. anonymous

    anonymous Guest

    The other companies will learn from Amgen's mistakes. They didn't have to do any DSE as Amgen did it all. The hub is behind, but that is to be expected with the high demand. Patient are suffering and this drug is effective. They have been waiting on it and the feedback is good.

    Amgen will pick up the pace of the hub and all will be happy. The comp plan is not fair, but there is not a lot anyone can do about it as Amgen is greedy and all about money and how much they bring into TO. The launch plan is the most pathetic anyone has seen for such a big drug and everyone doesn't think it's right. Few will make money and not even great money.
     
  9. anonymous

    anonymous Guest


    the comp plan is appropriate for the level of this sales force
     
  10. anonymous

    anonymous Guest

    We will stomp Amgen and are bringing our wallets to AHS. That's right, we are interviewing Amgen headquarter peeps during the AHS and are offering a 30% salary increase and an epic sign on. We will cherry pick your best then take all your customers next. Watch your launch sales trend line head south fools. We know exactly who we want and what we need to do and we are keenly aware of your internal shit show. People and customers talk you know.
     
  11. anonymous

    anonymous Guest

    True. Look at leader's board. They could do nothing and win.
    They designed the comp plan to reward few.

    I'm not worried about Teva though. Their sales force stinks.
     
  12. anonymous

    anonymous Guest


    You have an internal shit show too--tons of turnover--failed products, etc.

    One thing you're right on is that you'll get Amgen employees to come over-easily. no one is happy here with the micromanaging and poor pay. Amgen NuBu is a poorly paid division
     
  13. anonymous

    anonymous Guest


    Teva has transformed itself since the start of this year. New senior leadership as well as a much leaner sales & marketing organization (smaller headcount/better comp plans). Their R&D and home office support systems as well as a state of the art and totally revamped patient support and product pull through group, is poised to make the fremanizumab (Ajovi) migraine launch very exciting. All the old fluff is now gone and that's why the days of failed product launches and poor acquisition choices are over. Look at their Huntington's / TD drug Austedo. They are killing it and beating the pants off Neurocrine's product. Copaxone is still holding it's own despite a ton of oral and generic competition. Their pipeline is simply focused on CNS and Pain, so there won't be any distractions in other "Me Too" therapeutic areas. The stock is slowly moving up again with shareholder confidence and once all the consolidation for the new home office headquarters takes place, as opposed to 3 separate U.U. headquarter locations, watch out. I say all of this since I have done my due diligence on finding a new home for myself. The previous poster is not wrong. I am about to move over to be part of this new growth opportunity. And yes, with a greater than 30% bump in my previous Amgen salary. Being part of a much smaller biopharma organization with no drama and ego trips is the place for me!!!!
     
  14. anonymous

    anonymous Guest


    Amgen is not biotech. They micromanage worse than any Pharma company out there, and I've been at several other companies. Everyone outside of the company wants in. Everyone inside the company wants out. They have a big secret going.
     
  15. anonymous

    anonymous Guest

    The most true statement I've heard. Many people still think Amgen is the little biotech that used to be a great place to work in 1995. Those days are long gone and those who heard it's a great place, Amgen's reputation hasn't kept up
     
  16. anonymous

    anonymous Guest


    That poster IS spot on. Everyone in wants out. Everyone out does want in and try anything to get in.
     
  17. anonymous

    anonymous Guest

     
  18. anonymous

    anonymous Guest

    This is one of the funniest posts I've read!
     
  19. anonymous

    anonymous Guest


    Jealous aren't you? You just wish you could get out of your miserable job and get into something better.
     
  20. anonymous

    anonymous Guest

    Hilliarious